Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non Operating Income: 2016-2025

Historic Non Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $274,000.

  • Rhythm Pharmaceuticals' Non Operating Income fell 74.82% to $274,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 131.93%. This contributed to the annual value of $5.2 million for FY2024, which is 2059.26% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Non Operating Income stood at $274,000 for Q3 2025, which was down 82.61% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Non Operating Income peaked at $100.2 million during Q1 2021, and registered a low of -$2.4 million during Q1 2025.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Non Operating Income value was -$99,000 (recorded in 2023), while the average stood at $530,000.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Non Operating Income crashed by 1,255.07% in 2022, and later spiked by 8,883.84% in 2024.
  • Rhythm Pharmaceuticals' Non Operating Income (Quarterly) stood at $134,000 in 2021, then tumbled by 391.04% to -$390,000 in 2022, then soared by 55.90% to -$172,000 in 2023, then crashed by 1,136.63% to -$2.1 million in 2024, then crashed by 74.82% to $274,000 in 2025.
  • Its Non Operating Income stands at $274,000 for Q3 2025, versus $1.6 million for Q2 2025 and -$2.4 million for Q1 2025.